西亚试剂：Loss of oncogenic Notch1 with resistance to a PI3K inhibito

发布时间：2025-09-08

Monique Dail, Jason Wong, Jessica Lawrence, Daniel O’Connor, Joy Nakitandwe, Shann-Ching Chen, Jin Xu, Leslie B. Lee, Keiko Akagi, Qing Li, Jon C. Aster, Warren S. Pear,James R. Downing, Deepak Sampath & Kevin Shannon

Mutations that deregulate Notch1 and Ras/phosphoinositide 3 kinase (PI3K)/Akt signalling are prevalent in T-cell acute lymphoblastic leukaemia (T-ALL), and often coexist. Here we show that the PI3K inhibitor GDC-0941 is active against primary T-ALLs from wild-type and KrasG12D mice, and addition of the MEK inhibitor PD0325901 increases its efficacy. Mice invariably relapsed after treatment with drug-resistant clones, most of which unexpectedly had reduced levels of activated Notch1 protein, downregulated many Notch1 target genes, and exhibited cross-resistance to γ-secretase inhibitors. Multiple resistant primary T-ALLs that emerged in vivo did not contain somaticNotch1 mutations present in the parental leukaemia. importantly, resistant clones upregulated PI3K signalling. Consistent with these data, inhibiting Notch1 activated the PI3K pathway, providing a likely mechanism for selection against oncogenic Notch1 signalling. These studies validate PI3K as a therapeutic target in T-ALL and raise the unexpected possibility that dual inhibition of PI3K and Notch1 signalling could promote drug resistance in T-ALL.

以上资料由西亚试剂：http://www.xiyashiji.com/ 提供

上一篇：西亚试剂：Unraveling the structure of DNA during overstretching by us
下一篇：西亚试剂 ：Structural organization of an intact phycobilisome and it